NewsBenzingaPropanc Biopharma宣布新的临床前数据支持PRP治疗胰腺癌化疗耐药的潜力;PRP单药治疗使癌细胞增殖减少约50–54%,并将长期克隆形成存活率抑制高达59% Propanc Biopharma宣布新的临床前数据支持PRP治疗胰腺癌化疗耐药的潜力;PRP单药治疗使癌细胞增殖减少约50–54%,并将长期克隆形成存活率抑制高达59% Benzinga 2026.10.26 12:32 (GMT+0) Open on Benzinga Other news Motorola Solutions Hikes Quarterly Dividend From $1.21 To $1.34 Per Share These 9 Congress Members Could Have Increased Interest in Nvidia’s Q3 Earnings as 2026 Shareholders $100 Invested In Cigna Group 20 Years Ago Would Be Worth This Much Today Needham Maintains Buy on FuboTV, Lowers Price Target to $10 BTIG Reiterates Buy on Amer Sports, Maintains $42 Price Target If You Invested $1000 In Ulta Beauty Stock 15 Years Ago, You Would Have This Much Today